These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 22503160)

  • 21. Artificially low mild cognitive impairment to normal reversion rate in the Alzheimer's Disease Neuroimaging Initiative.
    Thomas KR; Eppig JS; Weigand AJ; Edmonds EC; Wong CG; Jak AJ; Delano-Wood L; Galasko DR; Salmon DP; Edland SD; Bondi MW;
    Alzheimers Dement; 2019 Apr; 15(4):561-569. PubMed ID: 30610833
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Plasma and cerebrospinal fluid amyloid beta for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).
    Ritchie C; Smailagic N; Noel-Storr AH; Takwoingi Y; Flicker L; Mason SE; McShane R
    Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD008782. PubMed ID: 24913723
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neuropsychological Decline Improves Prediction of Dementia Beyond Alzheimer's Disease Biomarker and Mild Cognitive Impairment Diagnoses.
    Nation DA; Ho JK; Dutt S; Han SD; Lai MHC;
    J Alzheimers Dis; 2019; 69(4):1171-1182. PubMed ID: 31104015
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Injury markers but not amyloid markers are associated with rapid progression from mild cognitive impairment to dementia in Alzheimer's disease.
    van Rossum IA; Visser PJ; Knol DL; van der Flier WM; Teunissen CE; Barkhof F; Blankenstein MA; Scheltens P
    J Alzheimers Dis; 2012; 29(2):319-27. PubMed ID: 22233766
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sample Size Estimation for Alzheimer's Disease Trials from Japanese ADNI Serial Magnetic Resonance Imaging.
    Fujishima M; Kawaguchi A; Maikusa N; Kuwano R; Iwatsubo T; Matsuda H; ;
    J Alzheimers Dis; 2017; 56(1):75-88. PubMed ID: 27911297
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Utility of combinations of biomarkers, cognitive markers, and risk factors to predict conversion from mild cognitive impairment to Alzheimer disease in patients in the Alzheimer's disease neuroimaging initiative.
    Gomar JJ; Bobes-Bascaran MT; Conejero-Goldberg C; Davies P; Goldberg TE;
    Arch Gen Psychiatry; 2011 Sep; 68(9):961-9. PubMed ID: 21893661
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alzheimer Disease Biomarkers as Outcome Measures for Clinical Trials in MCI.
    Caroli A; Prestia A; Wade S; Chen K; Ayutyanont N; Landau SM; Madison CM; Haense C; Herholz K; Reiman EM; Jagust WJ; Frisoni GB;
    Alzheimer Dis Assoc Disord; 2015; 29(2):101-9. PubMed ID: 25437302
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Metabolic syndrome biomarkers relate to rate of cognitive decline in MCI and dementia stages of Alzheimer's disease.
    Pillai JA; Bena J; Bekris L; Kodur N; Kasumov T; Leverenz JB; Kashyap SR;
    Alzheimers Res Ther; 2023 Mar; 15(1):54. PubMed ID: 36927447
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structural magnetic resonance imaging for the early diagnosis of dementia due to Alzheimer's disease in people with mild cognitive impairment.
    Lombardi G; Crescioli G; Cavedo E; Lucenteforte E; Casazza G; Bellatorre AG; Lista C; Costantino G; Frisoni G; Virgili G; Filippini G
    Cochrane Database Syst Rev; 2020 Mar; 3(3):CD009628. PubMed ID: 32119112
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Application of the NIA-AA Research Framework: Towards a Biological Definition of Alzheimer's Disease Using Cerebrospinal Fluid Biomarkers in the AIBL Study.
    Burnham SC; Coloma PM; Li QX; Collins S; Savage G; Laws S; Doecke J; Maruff P; Martins RN; Ames D; Rowe CC; Masters CL; Villemagne VL
    J Prev Alzheimers Dis; 2019; 6(4):248-255. PubMed ID: 31686097
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic classification of mild cognitive impairment and Alzheimer's disease: MRI independent component analysis.
    Willette AA; Calhoun VD; Egan JM; Kapogiannis D;
    Psychiatry Res; 2014 Nov; 224(2):81-8. PubMed ID: 25194437
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neuroimaging basis in the conversion of aMCI patients with APOE-ε4 to AD: study protocol of a prospective diagnostic trial.
    Chen GQ; Sheng C; Li YX; Yu Y; Wang XN; Sun Y; Li HY; Li XY; Xie YY; Han Y
    BMC Neurol; 2016 May; 16():64. PubMed ID: 27176479
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association of peripheral blood DNA methylation level with Alzheimer's disease progression.
    Li QS; Vasanthakumar A; Davis JW; Idler KB; Nho K; Waring JF; Saykin AJ;
    Clin Epigenetics; 2021 Oct; 13(1):191. PubMed ID: 34654479
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Visual Evaluation of Medial Temporal Lobe Atrophy as a Clinical Marker of Conversion from Mild Cognitive Impairment to Dementia and for Predicting Progression in Patients with Mild Cognitive Impairment and Mild Alzheimer's Disease.
    Persson K; Barca ML; Eldholm RS; Cavallin L; Šaltytė Benth J; Selbæk G; Brækhus A; Saltvedt I; Engedal K
    Dement Geriatr Cogn Disord; 2017; 44(1-2):12-24. PubMed ID: 28614836
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Alzheimer's Disease Neuroimaging Initiative phase 2: Increasing the length, breadth, and depth of our understanding.
    Beckett LA; Donohue MC; Wang C; Aisen P; Harvey DJ; Saito N;
    Alzheimers Dement; 2015 Jul; 11(7):823-31. PubMed ID: 26194315
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cognitive reserve and Alzheimer's disease biomarkers are independent determinants of cognition.
    Vemuri P; Weigand SD; Przybelski SA; Knopman DS; Smith GE; Trojanowski JQ; Shaw LM; Decarli CS; Carmichael O; Bernstein MA; Aisen PS; Weiner M; Petersen RC; Jack CR;
    Brain; 2011 May; 134(Pt 5):1479-92. PubMed ID: 21478184
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Machine Learning Predictive Models Can Improve Efficacy of Clinical Trials for Alzheimer's Disease.
    Ezzati A; Lipton RB;
    J Alzheimers Dis; 2020; 74(1):55-63. PubMed ID: 31985462
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of
    Qian J; Betensky RA; Hyman BT; Serrano-Pozo A
    Neurology; 2021 May; 96(19):e2414-e2428. PubMed ID: 33771840
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Harnessing peripheral DNA methylation differences in the Alzheimer's Disease Neuroimaging Initiative (ADNI) to reveal novel biomarkers of disease.
    Vasanthakumar A; Davis JW; Idler K; Waring JF; Asque E; Riley-Gillis B; Grosskurth S; Srivastava G; Kim S; Nho K; Nudelman KNH; Faber K; Sun Y; Foroud TM; Estrada K; Apostolova LG; Li QS; Saykin AJ;
    Clin Epigenetics; 2020 Jun; 12(1):84. PubMed ID: 32539856
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association of Apolipoprotein E ε4 With Medial Temporal Tau Independent of Amyloid-β.
    Therriault J; Benedet AL; Pascoal TA; Mathotaarachchi S; Chamoun M; Savard M; Thomas E; Kang MS; Lussier F; Tissot C; Parsons M; Qureshi MNI; Vitali P; Massarweh G; Soucy JP; Rej S; Saha-Chaudhuri P; Gauthier S; Rosa-Neto P
    JAMA Neurol; 2020 Apr; 77(4):470-479. PubMed ID: 31860000
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.